Apollo Endosurgery, Inc. (NASDAQ:APEN) Director Richard J. Meelia acquired 45,454 shares of the stock in a transaction that occurred on Tuesday, July 25th. The stock was purchased at an average price of $5.50 per share, with a total value of $249,997.00. Following the completion of the transaction, the director now owns 5,098 shares of the company’s stock, valued at $28,039. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Apollo Endosurgery, Inc. (NASDAQ:APEN) opened at 6.08 on Monday. Apollo Endosurgery, Inc. has a 12-month low of $4.96 and a 12-month high of $22.27. The stock’s 50 day moving average price is $6.92 and its 200 day moving average price is $9.40. The company’s market cap is $65.11 million.

Apollo Endosurgery (NASDAQ:APEN) last released its earnings results on Tuesday, August 1st. The biotechnology company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by $0.40. Apollo Endosurgery had a negative net margin of 81.59% and a negative return on equity of 142.98%. The company had revenue of $17.14 million during the quarter. Equities research analysts anticipate that Apollo Endosurgery, Inc. will post ($1.15) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Apollo Endosurgery, Inc. (APEN) Director Acquires $249,997.00 in Stock” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/08/07/apollo-endosurgery-inc-apen-director-richard-j-meelia-acquires-45454-shares-of-stock-updated.html.

Several equities analysts have recently issued reports on APEN shares. Roth Capital started coverage on Apollo Endosurgery in a research report on Wednesday, August 2nd. They set a “buy” rating and a $10.00 target price for the company. ValuEngine lowered Apollo Endosurgery from a “sell” rating to a “strong sell” rating in a research report on Thursday. Finally, Craig Hallum started coverage on Apollo Endosurgery in a research report on Monday, July 24th. They set a “buy” rating and a $11.00 target price for the company.

About Apollo Endosurgery

Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.

Insider Buying and Selling by Quarter for Apollo Endosurgery (NASDAQ:APEN)

Receive News & Stock Ratings for Apollo Endosurgery Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery Inc. and related stocks with our FREE daily email newsletter.